Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


J Am Soc Nephrol 16: 64-66, 2005
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2004110969
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Segura, J.
Right arrow Articles by Ruilope, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Segura, J.
Right arrow Articles by Ruilope, L. M.

Calcium Channel Blockers and Renal Protection: Insights from the Latest Clinical Trials

Julián Segura, José A. García-Donaire and Luis M. Ruilope

Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain

Address correspondence to: Dr. Luis M Ruilope, Hypertension Unit, Hospital 12 de Octubre, Avenue Córdoba s/n, 28041 Madrid, Spain. Phone: 34-91-3908198; Fax: 34-91-3908035; E-mail: ruilope{at}ad-hocbox.com

Calcium channel blockers have been widely used in clinical practice because of their antihypertensive capacity. Prevention of renal damage is a very important aim of antihypertensive therapy. This is particularly so taking into account the high prevalence of chronic kidney disease (CKD) in the general population. Recent data have shown that CKD is related to the absence of adequate BP control and also to the clustering of other cardiovascular risk factors seen in the metabolic syndrome. The knowledge of the capacities of the different antihypertensive drugs or their combinations to simultaneously control BP while protecting the kidney and avoiding the facilitation of metabolic alterations is warranted. Recent data from the Intervention as a Goal in Hypertension Treatment trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and African American Study of Kidney Disease and Hypertension (AASK) allow the conclusion that in hypertensive patients with preserved renal function or with CKD, calcium channel blockers are effective antihypertensive drugs to be considered alone or in combination with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker.




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
N. Kondo, H. Kiyomoto, T. Yamamoto, A. Miyatake, G.-P. Sun, M. Rahman, H. Hitomi, K. Moriwaki, T. Hara, S. Kimura, et al.
Effects of Calcium Channel Blockade on Angiotensin II-Induced Peritubular Ischemia in Rats
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1047 - 1052.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673